While physicians might differentiate between the various blood vessel anatomies, lipids and platelets do not. Occlusions in the coronary arteries are usually accompanied by at-risk build-ups in the peripheral vasculature as well. More than 50 percent of patients with arterial diseases fail to show a reduction in disease progression with pharmaceutical therapy alone. More than 40 percent of arterial disease patients are not candidates for risky by-pass procedures. Minimally invasive catheter interventions reduces procedure times, recovery time, and have overall higher clinical rates of success. Advances in catheter technology and cardiovascular imaging techniques are spurring thrombectomy and atherectomy device usage.
New analysis from Frost & Sullivan, U.S. Atherectomy and Thrombectomy Devices Market, reveals that revenues in this market totaled $266.2 million in 2005, and can reach $863.8 million in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Atherectomy and Thrombectomy Devices Market then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
“The peripheral market is seen as the next major growth opportunity for market participants in the cardiovascular arena, and its vast potential is attracting competitors from all levels of the medical device industry,” notes Frost & Sullivan Industry Analyst Venkat Rajan. “In the United States, each year, an estimated 175,000 bypass procedures and 160,000 amputations are performed as a result of advanced stage peripheral vascular disease. Advanced detection and preventative measures such as atherectomy and thrombectomy procedures could reduce the percentage of patients requiring amputation by 80 percent.”
Advances in imaging, navigation, and catheter capabilities are a crucial driver for expanding atherectomy and thrombectomy device usage. Technological advances such as on-board imaging capabilities or localized drug delivery could be a major component of future device offerings.
A major concern preventing the full-scale usage of atherectomy and thrombectomy devices is the inherent safety issues attached to them. Since each of these devices uses some sort of force to remove or destroy obstructions, there exists the risk of causing blunt trauma to the vessel walls. Any sort of trauma can lead to weakening of vessels, possible rupture, or scar formation resulting in collateral damage.
“Occlusions in delicate regions such as the cerebral vasculature had been previously been un-addressable,” notes Rajan. “Furthermore clinical data itself is no longer taken simply at face value, and a number of clinicians in addition to the actual devices evaluate the thoroughness of the trial itself.”
In order to overcome these challenges, market participants could make greater use of head-to-head clinical trial data. Additional strategies involve grass roots marketing techniques to help establish market foothold, and deferred capital equipment costs to incentivize adoption. As in other markets direct to patient marketing is helping expand the general knowledge of available treatment options capable of addressing advanced cardiovascular diseases.
U.S. Atherectomy and Thrombectomy Devices Market is part of the Medical Device Subscription, which also includes research in the following markets: U.S. Carotid and Intracranial Devices, U.S. Angioplasty and Vascular Closure Markets, and the U.S. Peripheral Stent and Stent Grafts Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.